Cardiff Oncology, Inc. · NASDAQ:CRDF

Cardiff Oncology — Corporate Update (September 2023)

26 slides from Cardiff Oncology's corporate update, Sep 26, 2023

  1. Slide 1: Pancreatic Cancer and Small Cell Lung Cancer Program Updates

    Pancreatic Cancer and Small Cell Lung Cancer Program Updates

  2. Slide 2: Forward-looking statements

    Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other sim

  3. Slide 3: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) and Small Cell Lung Cancer (SCLC)

    Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • • • Small Cell Lung Cancer (SCLC) •

  4. Slide 4: Onvansertib specificity and properties

    Onvansertib SPECIFICITYPROPERTIES • • •

  5. Slide 5: Line of therapy and combination trials

    Line of Therapy Ph2 Ph3 Combination with:Trial IIT*

  6. Slide 6: Annual eligible U.S. patients by target

    Targets with oncogenic alterations Targets without oncogenic alterations * ROS1 estimated eligible patients presented in Turning Point Therapeutics’ corporate presentation May 2022 slide 6 (NSCLC disease incidence in the US of 140k of which 2% of patients harbor ROS1 translocation). RET estimated el

  7. Slide 7: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

    Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Small Cell Lung Cancer (SCLC)

  8. Slide 8: mPDAC CRDF-001 second-line trial

    mPDAC CRDF-001 Ph 2 Second-Line Trial • mPDAC Biomarker Discovery Trial (IIT) • Path forward: Move to 1st line mPDAC •

  9. Slide 9: mPDAC CRDF-001 second-line trial

    mPDAC CRDF-001 Ph 2 Second-Line Trial • mPDAC Biomarker Discovery Trial (IIT) • Path forward: Move to 1st line mPDAC •

  10. Slide 10: Trial design, endpoints and objectives

    14 DAY CYCLE ENROLLMENT CRITERIA OBJECTIVE PRIMARY ENDPOINT SECONDARY ENDPOINT

  11. Slide 11: Confirmed PR and waiting for confirmatory scan

    Confirmed PR Waiting for confirmatory scan

  12. Slide 12: Stable disease patients have converted to partial responses over time

    Stable disease patients have converted to partial responses over time Swimmer plot — 23 evaluable patients (as of September 13, 2023)* 0 ie] Reason for Discontinuation fo) fo) Adverse Event ° 5. Death Disease Progression — e © Withdrawal of Informed Consent e Pe0t05%o,0 ° ° peonen oe % fe} © Progres

  13. Slide 13: Confirmed PR waiting for confirmatory scan

     Confirmed PR Waiting for confirmatory scan

  14. Slide 14: Onvansertib+SoC has longer median PFS than 2nd line historical controls

    Onvansertib+SoC has longer median PFS than 2" line historical controls Progression-free survival - 23 evaluable patients (as of September 13, 2023)* g 1.004 s Historical controls! g 2sline 1% line 20751 CRDF-001 mPDAC mPDAC 3 & mPFS 5.0mos 3.1mos 5.5 mos 0.50; 16 week Net progression- 56% ‘labl 48%

  15. Slide 15: mPDAC CRDF-001 second-line trial

    mPDAC CRDF-001 Ph 2 Second-Line Trial • mPDAC Biomarker Discovery Trial (IIT) • Path forward: Move to 1st line mPDAC •

  16. Slide 16: Biomarker discovery trial objectives and enrollment criteria

    • • OBJECTIVESENROLLMENT CRITERIA

  17. Slide 17: Biomarker patient data: tumor responder vs non-responder

    Patient 28 (tumor responder) 0 10 20 30 0k 50k 100k 150k Patient 33 (tumor non-responder) 0 10 20 30 40 0 500 1000 1500 • •     

  18. Slide 18: mPDAC path forward: move to 1st line

    mPDAC CRDF-001 Ph 2 Second-Line Trial • mPDAC Biomarker Discovery Trial (IIT) • Path forward: Move to 1st line mPDAC •

  19. Slide 19: First-line mPDAC trial design

    ENROLLMENT CRITERIA 28 DAY CYCLE TWO LEAD-IN COHORTS SUBSEQUENT CHEMO + ONVANSERTIB TREATMENT* • • PRIMARY ENDPOINT SECONDARY ENDPOINTS

  20. Slide 20: Small Cell Lung Cancer (SCLC)

    Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Small Cell Lung Cancer (SCLC)

  21. Slide 21: Onvansertib demonstrates single-agent activity in preclinical SCLC models

    Onvansertib demonstrates single-agent activity in preclinical SCLC models TRIAL RATIONALE In vivo efficacy of onvansertib monotherapy (SCLC xenografts)* Onvansertib monotherapy _ CISPLATIN RESISTANT CISPLATIN SENSIVITVE showed significant tumor = 2000 2000 growth inhibition against S son. platinum-s

  22. Slide 22: SCLC trial design and endpoints

    ENROLLMENT CRITERIA 21 DAY CYCLE PRIMARY ENDPOINT SECONDARY ENDPOINTS OBJECTIVE

  23. Slide 23: SCLC preliminary efficacy and safety

    ENROLLMENT CRITERIA PRELIMINARY EFFICACY (N=7) PRELIMINARY SAFETY (N=6)

  24. Slide 24: Baseline scan and restaging after cycle

    Baseline Scan Restaging after Cycle 2

  25. Slide 25: Upcoming data readouts 2023-2025

    20252023 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1st line mCRC randomized data readout mPDAC data readout SCLC data readout

  26. Slide 26: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) and Small Cell Lung Cancer (SCLC)

    Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • • • Small Cell Lung Cancer (SCLC) •

Cardiff Oncology — Corporate Update (September 2023) on 6ix